ReviewCurrent rheumatology reports2019
Strategies to Improve Outcomes in Psoriatic Arthritis.
Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.JAMA dermatology · 2025Article
- Burden and determinants of multi-b/tsDMARD failure in psoriatic arthritis.Arthritis research & therapy · 2025Observational
- Multidisciplinary Management of Psoriasis: Integrating Diet, Exercise, Psychological Support, and Sleep Interventions.Clinical, cosmetic and investigational dermatology · 2025Review
- Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis.The Journal of rheumatology · 2024Article
- Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.RMD open · 2024Article
- Disease Profile and Achievement of Therapeutic Goals in a Modern, Nationwide Cohort of 923 Patients with Psoriatic Arthritis.Mediterranean journal of rheumatology · 2023Article
- Article
- New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine.The Journal of investigative dermatology · 2021Review
- Psoriatic arthritis.Nature reviews. Disease primers · 2021Review
- Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.Rheumatology (Oxford, England) · 2021Article
- Pain Control in Dermatologic Conditions.Current pain and headache reports · 2021Review
- Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study.Nature reviews. Rheumatology · 2021Review
- Clinicians' perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: an interview study.Clinical rheumatology · 2021Article
- Navigating the diverse immune landscapes of psoriatic arthritis.Seminars in immunopathology · 2021Review
- Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN.Current rheumatology reports · 2020Review
- First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study.Sao Paulo medical journal = Revista paulista de medicinaObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe therapeutic response to biologic agents in psoriasis is significantly higher than observed in psoriatic arthritis (PsA). In this review, specific actions to improve treatment outcomes in PsA are discussed. RECENT
findingsIncreased understanding of disease pathogenesis derived from improved preclinical models and advances in cell-based and molecular technologies provide new tools to identify therapeutic targets. In addition to the important contributions of metabolic comorbidities, chronic pain and the lack of a diagnostic biomarker signal the need for new strategies to improve outcomes. Potential strategies include the following: (1) discover a novel pathway or cellular subset, (2) apply stratification biomarkers to individualize therapy, (3) preclinical intervention, (4) combination therapy, (5) lifestyle modification, (6) address chronic pain and fatigue, and (7) multidisciplinary care. The future holds great promise for enhanced treatment responses in PsA based on improved understanding of individual variation in disease pathophysiology coupled with comprehensive and integrated treatment programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.